Sign In
Buy HALO
$69.82
+3.54 (+5.34%)
At Close: Jun 03, 2026
SAN DIEGO, June 22, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission (EC) has granted the Janssen Pharmaceutical Companies of Johnson & John
GSK- Pfizer's ViiV To Develop 'Ultra-Long-Acting' HIV Drugs With $215M Halozyme Deal
06:29am, Tuesday, 22'nd Jun 2021
GlaxoSmithKline plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), and Shionogi Limited owned ViiV Healthcare has collaborated with Halozyme Therapeutics Inc (NASDAQ: HALO) to gain access to Halozyme's
LONDON & SAN DIEGO--(BUSINESS WIRE)--ViiV HC and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to develop ultra-long-acting HIV medicines
LONDON and SAN DIEGO, June 22, 2021 /PRNewswire/ -- ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc ("GSK"), with Pfizer Inc. and Shionogi Limited as sharehol
SAN DIEGO, June 1, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced abstracts and presentations by its collaborators for the 2021 American Society of Clinical Oncology (
Halozyme to Present at Upcoming Investor Conferences
04:40pm, Friday, 28'th May 2021
SAN DIEGO, May 28, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it will participate at the following investor conferences: The Goldman Sachs 42nd Annual Global
Halozyme: A Stalwart With More Upside
05:42pm, Friday, 21'st May 2021
Halozyme is currently in the stalwart phase with approximately less than 50% more upsides.The company shifted focus to employing a low-risk business model. They're out-licensing their Enhanze technolo
SAN DIEGO, May 21, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Pharmaceutica N.V. (Janssen) received two positive opinions from the Committee for Me
Halozyme (HALO) Stock Down Despite Q1 Earnings & Sales Beat
12:02pm, Tuesday, 11'th May 2021
Halozyme (HALO) first-quarter earnings and sales beat estimates. The company retains 2021 guidance.
Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q1 2021 Results - Earnings Call Transcript
11:08pm, Monday, 10'th May 2021
Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q1 2021 Results - Earnings Call Transcript
Halozyme Therapeutics (HALO) Tops Q1 Earnings and Revenue Estimates
06:47pm, Monday, 10'th May 2021
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 19.35% and 5.19%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Reports First Quarter 2021 Results
04:01pm, Monday, 10'th May 2021
SAN DIEGO, May 10, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the first quarter ended March 31, 2021 and provided an update on its recent co
Halozyme To Host First Quarter 2021 Financial Results Webcast And Conference Call
04:05pm, Tuesday, 20'th Apr 2021
SAN DIEGO, April 20, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2021 on Monday, May 10 at 4:30 p.m. ET / 1
Would Halozyme Make a Good Warren Buffett Stock?
06:12am, Sunday, 04'th Apr 2021
In some ways, this healthcare stock is outside his wheelhouse. But there could be attractions.
2 Overvalued Biotech Stocks Still Worth Buying
06:33am, Thursday, 04'th Mar 2021
Sometimes valuation metrics can be deceiving.
